TaiMed Biologics Inc. reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported sales was TWD 99.29 million compared to TWD 155.2 million a year ago. Net loss was TWD 75.77 million compared to TWD 99.26 million a year ago. Basic loss per share from continuing operations was TWD 0.3 compared to TWD 0.39 a year ago. Diluted loss per share from continuing operations was TWD 0.3 compared to TWD 0.39 a year ago.
For the six months, sales was TWD 139.96 million compared to TWD 246.46 million a year ago. Net loss was TWD 195.53 million compared to TWD 94.35 million a year ago. Basic loss per share from continuing operations was TWD 0.77 compared to TWD 0.37 a year ago. Diluted loss per share from continuing operations was TWD 0.77 compared to TWD 0.37 a year ago.